Erratum: Prediction of cardiovascular events in statin-treated patients by lipid and non-lipid biomarkers (Journal of the American College of Cardiology (2011) 57 (63-69))
Benoit J. Arsenault,Philip J. Barter,David A. DeMicco,Weihang Bao,Gregory M. Preston,John C. LaRosa,Scott M. Grundy,Prakash Deedwania,Heiner Greten,Nanette K. Wenger,James Shepherd,David D. Waters,John J.P. Kastelein +12 more
About:
This article is published in Journal of the American College of Cardiology.The article was published on 2013-04-23 and is currently open access. It has received 1 citations till now.read more
Citations
More filters
Journal ArticleDOI
Prediction of cardiovascular events in statin-treated stable coronary patients of the treating to new targets randomized controlled trial by lipid and non-lipid biomarkers.
Benoit J. Arsenault,Philip J. Barter,David A. DeMicco,Weihang Bao,Gregory M. Preston,John C. LaRosa,Scott M. Grundy,Prakash Deedwania,Heiner Greten,Nanette K. Wenger,James Shepherd,David D. Waters,John J.P. Kastelein +12 more
TL;DR: In patients with CHD treated with atorvastatin, plasma levels of Lp(a), neopterin, NT-proBNP, and sRAGE are associated with the risk of recurrent MCVEs.
References
More filters
Journal ArticleDOI
Intensive lipid lowering with atorvastatin in patients with stable coronary disease.
John C. LaRosa,Scott M. Grundy,David D. Waters,Charles L. Shear,Philip J. Barter,Jean Charles Fruchart,Antonio M. Gotto,Heiner Greten,John J.P. Kastelein,James Shepherd,Nanette K. Wenger +10 more
TL;DR: Intensive lipid-lowering therapy with 80 mg of atorvastatin per day in patients with stable CHD provides significant clinical benefit beyond that afforded by treatment with 10 mg of least-in- LDL cholesterol levels per day, with a greater incidence of elevated aminotransferase levels.